Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04843579 · ClinicalTrials.gov registry record · Phase 2
Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT04843579 is a Phase 2 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 4 participants.
The verdict
NCT04843579, a Phase 2 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy and safety of investigational combination therapy of Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd) for patients with relapsed/refractory multiple myeloma. The hypothesis is that the addition of Selinexor to Clarithromycin, Pomalidomide and Dexamethasone will increase the overall response rate of patients with relapsed/refractory multiple myeloma.
Interventions
- DRUG Selinexor
- DRUG Dexamethasone
- DRUG Pomalidomide
- DRUG Clarithromycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2021-12-29 |
| Est. Completion | 2022-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04843579
The ClinicalTrials.gov registry entry for NCT04843579 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Selinexor is the first listed.
NCT04843579 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04843579 about?
NCT04843579 is a clinical study titled "Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients". The purpose of this study is to determine the efficacy and safety of investigational combination therapy of Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd) for patients with relapsed/refractory multiple myeloma. The hypothesis is that the addition of Selinexor to Clarithromycin, P...
What is the current status of trial NCT04843579?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2021-12-29. Estimated completion is 2022-12-30.
What interventions are being tested in trial NCT04843579?
The interventions under investigation include: Selinexor (DRUG), Dexamethasone (DRUG), Pomalidomide (DRUG), Clarithromycin (DRUG).
Who is sponsoring clinical trial NCT04843579?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.